Join to access to all OVN content. Join for Free

Results for 'Professional Challenges'

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 20th • 8 mins read

...
Partner Avatar Tom Caravela
Promotability: How to Land Your Next Promotion

May 5th • 10 mins read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
Partner Avatar Tom Caravela
What to do When a Job Offer is Rescinded

Jul 20th • 5 mins read

...
Partner Avatar iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 3rd • 1 min read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins read

...
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 8th • 4 mins read

...
OVN Avatar Ioannis Tsagakis and Maria Papatriantafyllou
Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic

Nov 22nd • 3 mins read

...
OVN Avatar Siddharth Agrawal, Nidhi Bansal
Advances and Challenges in Pediatric and Childhood Cancers

Jun 27th • 2 mins read

...
OVN Avatar Ramez Kouzy , Joseph Abi Jaoude , Walker Mainwaring , Timothy A. Lin , Austin B. Miller , Amit Jethanandani , Andres F. Espinoza , Vivek Verma , Clifton D. Fuller , Bruce D. Minsky , Claus Rödel , Cullen M. Taniguchi , Ethan B. Ludmir
Professional Medical Writer Assistance in Oncology Clinical Trials

Sep 17th • 7 mins read

...
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Aug 16th • 8 mins read

...
OVN Avatar Dean Bottino, Rachael Liu, Hojjat Bazzazi, Karthik Venkatakrishnan
Quantitative Translation in Immuno-Oncology Research and Development

Jul 9th • 3 mins read

...
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Jun 18th • 30 mins read

...
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

May 21st • 8 mins read

...
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD
Outcome measures for oncology alternative payment models: practical considerations and recommendations

Dec 1st • 10 mins read

...
OVN Avatar S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar
New Realities of Phase I Clinical Trials in the Era of

Oct 7th • 5 mins read

...
OVN Avatar Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

Sep 20th • 12 mins read

...
OVN Avatar M. Ochoa de Olza, M. Oliva, C. Hierro I. Matos, J. Martin-Liberal, E. Garralda
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Jun 26th • 26 mins read

...
OVN Avatar Rinda Devi Bachu, Mariam Abou-Dahech, Swapnaa Balaji, Sai H. S. Boddu, Samson Amos, Vishal Singh, R. Jayachandra Babu, Amit K. Tiwari
Oncology biosimilars: New developments and future directions

Nov 25th • 30 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9th • 5 mins read